15 Best Biotech Stocks to Buy According to Wall Street Analysts

Page 5 of 14

10. Praxis Precision Medicines Inc. (NASDAQ:PRAX)

Stock Upside Potential: 49.20%

Number of Hedge Fund Holders: 33

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Praxis Precision Medicines Inc. (NASDAQ:PRAX) affirmed successful completion of a pre-New Drug Application meeting with the US Food and Drug Administration for Ulixacaltamide, its investigational oral drug for essential tremor (ET). The company hopes to submit a New Drug Application early next year.

The company also confirmed positive results from the EMBOLD study evaluating riluzole for patients with SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEEs). The positive results included a 53% placebo-adjusted reduction in seizures and no serious adverse events.

Meanwhile, analysts at TD Cowen have reiterated a Buy rating on the stock and increased the price target to $353 from $251. Praxis presented updated Phase 2 RADIANT trial data at AES 2025 showing its candidate vormatrigine achieved nearly 100% median seizure reduction in focal onset seizures and about 80% in generalized epilepsy, while interim EMBOLD results revealed relutrigine delivered a 53% placebo-adjusted reduction with continued benefits in the open-label extension; following these findings, TD Cowen raised its price target on Praxis to $353, reflecting confidence in the company’s epilepsy pipeline.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is a clinical-stage biotech company developing targeted therapies for severe brain disorders like epilepsy, depression, and movement disorders.

Page 5 of 14